Acrivon Therapeutics, Inc.: management transactions · United States · SEC (Form 4) Browse the full management transaction log of Acrivon Therapeutics, Inc., a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €60.8m. The latest transaction was filed on 26 May 2026 (Retenue fiscale). Among the most active insiders: Blume-Jensen Peter. The full history is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 26 May 2026
All Executives90 Thresholds0 Prospectus0 Other0
Declarations 90 total
● President and CEO · Executives · 21 May 2026
13,729 shares @ US$1.79 0.5% of flow Common Stock SEC:0000905148-26-002652:0
● Chief Legal Officer · Executives · 17 Apr 2026
558 shares @ US$1.78 1.9% of flow Common Stock SEC:0000905148-26-001768:0
● President and CEO · Executives · 21 Feb 2026
14,265 shares @ US$1.53 0.5% of flow Common Stock SEC:0000905148-26-001010:0
● President and CEO · Executives · 21 Nov 2025
19,904 shares @ US$2.30 1.0% of flow Common Stock SEC:0000905148-25-004179:0
● President and CEO · Executives · 14 Nov 2025
59,765 shares @ US$2.24 2.9% of flow Common Stock SEC:0000905148-25-004127:0
● President and CEO · Executives · 14 Nov 2025
490 shares @ US$2.24 0.0% of flow Common Stock SEC:0000905148-25-004127:1
● Chief Operating Officer · Executives · 14 Nov 2025
613 shares @ US$2.24 2.3% of flow Common Stock SEC:0000905148-25-004128:0
● Chief Development Officer · Executives · 14 Nov 2025
403 shares @ US$2.24 3.8% of flow Common Stock SEC:0000905148-25-004129:0
● Chief Legal Officer · Executives · 14 Nov 2025
184 shares @ US$2.24 0.8% of flow Common Stock SEC:0000905148-25-004130:0
● Chief Accounting Officer · Executives · 14 Nov 2025
99 shares @ US$2.24 6.3% of flow Common Stock SEC:0000905148-25-004131:0
● Chief Legal Officer · Executives · 17 Oct 2025
558 shares @ US$1.81 1.9% of flow Common Stock SEC:0000905148-25-003637:0
● Chief Financial Officer · Executives · 1 Aug 2025
1,164 shares @ US$1.26 100.0% of flow Common Stock SEC:0000905148-25-002732:0
● President and CEO · Executives · 21 May 2025
19,904 shares @ US$1.15 0.5% of flow Common Stock SEC:0000905148-25-001900:0
● Chief Legal Officer · Executives · 14 May 2025
184 shares @ US$1.14 0.4% of flow Common Stock SEC:0000905148-25-001823:0
● Chief Accounting Officer · Executives · 14 May 2025
99 shares @ US$1.14 3.3% of flow Common Stock SEC:0000905148-25-001824:0
● Chief Operating Officer · Executives · 14 May 2025
613 shares @ US$1.14 1.2% of flow Common Stock SEC:0000905148-25-001821:0
● Chief Development Officer · Executives · 14 May 2025
403 shares @ US$1.14 2.0% of flow Common Stock SEC:0000905148-25-001822:0
● President and CEO · Executives · 14 May 2025
59,766 shares @ US$1.14 1.5% of flow Common Stock SEC:0000905148-25-001820:0
437,881 shares @ US$1.41 2.5% of flow Common Stock SEC:0001062993-25-008341:0
1,054,669 shares @ US$1.95 8.4% of flow Common Stock SEC:0001062993-25-008214:0
▼ 10% Owner · Executives · 28 Apr 2025
215,283 shares @ US$1.56 1.4% of flow Common Stock SEC:0001062993-25-008214:1
▼ 10% Owner · Executives · 29 Apr 2025
250,000 shares @ US$1.41 1.4% of flow Common Stock SEC:0001062993-25-008214:2
● Chief Legal Officer · Executives · 17 Apr 2025
558 shares @ US$1.81 1.9% of flow Common Stock SEC:0000905148-25-001257:0
● President and CEO · Executives · 21 Feb 2025
19,904 shares @ US$5.54 2.6% of flow Common Stock SEC:0000905148-25-000764:0
● Chief Development Officer · Executives · 14 Feb 2025
469 shares @ US$5.42 11.9% of flow Common Stock SEC:0000905148-25-000727:0
25 of 90 declarations
Load more (65 remaining)